Reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Aram Barlezizyan, Professor Emeritus Aram Barlézizian at the Yerevan State Linguistic University after V. Brusov. Armenia Guy Bennett, American writer and translator, Professor at Otis College of Art and Design Bruno Bernard, Belgian professor and writer on export and business ethics Roméo Bosetti, Italian-born silent film director and actor. Louis Dewis, born Isidore Louis Dewachter in Belgium. Merchant and later a post-impressionist painter, he was honoured for his civic endeavors in the early 1900s Edith Dumont, Lieutenant Governor of Ontario Ahmed H. Fahal (2017), Professor of Surgery at the University of Khartoum, who especially in Mycetoma. Allan L. Goldstein, American biochemist and co-discoverer of the Thymosins Mary Riter Hamilton, Canada's first female battlefield artist Michael Hawcroft, Associate Professor of French at the University of Oxford, a specialist in Racine and Molière. Notable former students include L. Inglesfield and Geoffrey Roberts. Ralph M. Hester, Professor of French, Stanford University, co-author of Découverte et Création, the most widely used textbook for teaching French in the United States in the 1970s and 1980s. A. Majeed Khan, Bangladeshi educator for education, science and culture. Jihane Kasshanna, Lebanese founder of the SFELK French school in Northern Nigeria, the only one of its kind in the region James A. Kilker, Southern Illinois professor Emeritus, a specialist in French civilization, Kilker was known for his courses on French influence in the Mississippi Valley, which included tours of historic sites at St.
Research or investigator INDs are non-commercial INDs filed by researchers to study an unapproved drug or to study an approved drug for a new indication or in a new patient population. Emergency Use INDs, also called compassionate use or single-patient INDs, are filed for emergency use of an unapproved drug when the clinical situation does not allow sufficient time to submit an IND in accordance with 21 CFR §§ 312.23, 312.24. These are most commonly used for life-threatening conditions for which there is no standard treatment. Treatment INDs are filed to make a drug available for the treatment of serious or immediately life-threatening conditions prior to FDA approval. Serious diseases or conditions are stroke, schizophrenia, rheumatoid arthritis, osteoarthritis, chronic depression, seizures, Alzheimer's dementia, amyotrophic lateral sclerosis (ALS), and narcolepsy. Screening INDs are filed for multiple, closely related compounds in order to screen for the preferred compounds or formulations. The preferred compound can then be developed under a separate IND. Used for screening different salts, esters and other drug derivatives that are chemically different, but pharmacodynamically similar.
=== Plan-generate-test paradigm === The plan-generate-test paradigm is the basic organization of the problem-solving method, and is a common paradigm used by both Heuristic Dendral and Meta-Dendral systems. The generator (later named CONGEN) generates potential solutions for a particular problem, which are then expressed as chemical graphs in Dendral. However, this is feasible only when the number of candidate solutions is minimal. When there are large numbers of possible solutions, Dendral has to find a way to put constraints that rules out large sets of candidate solutions. This is the primary aim of Dendral planner, which is a “hypothesis-formation” program that employs “task-specific knowledge to find constraints for the generator”. Last but not least, the tester analyzes each proposed candidate solution and discards those that fail to fulfill certain criteria. This mechanism of plan-generate-test paradigm is what holds Dendral together.
2GO Group, Inc. (branded as 2GO) is a Philippine logistics and transportation company engaged in freight shipping, courier and parcel delivery, warehousing, inventory management, distribution, and passenger sea travel. It operates a fleet of ten inter-island vessels transporting cargo and passengers across domestic routes in the Philippines. The company traces its roots to William Lines, Inc., which was established on May 26, 1949. William Lines grew to become one of the largest shipping companies in the Philippines during the 1970s to the 1990s, before eventually merging with other domestic shipping firms that later formed what is now known as 2GO Group, Inc. 2GO is a subsidiary of SM Investments Corporation (SMIC), one of the country's largest conglomerates. Another principal shareholder is Trident Investments.
Sources: en.wikipedia.org
== Side effects == Possible adverse effects include bleeding disorder and allergic reactions such as flushing, stinging, generalised urticaria, angioedema, bronchospasm, and anaphylaxis. Other adverse effects in studies occurred in roughly equal proportions in treatment and placebo groups.
An initial tree, Ti, is randomly selected. A neighbour tree, Tj, is selected from the collection of trees. The ratio, R, of the probabilities (or probability density functions) of Tj and Ti is computed as follows: R = f(Tj)/f(Ti) If R ≥ 1, Tj is accepted as the current tree. If R < 1, Tj is accepted as the current tree with probability R, otherwise Ti is kept. At this point the process is repeated from Step 2 N times. The algorithm keeps running until it reaches an equilibrium distribution. It also assumes that the probability of proposing a new tree Tj when we are at the old tree state Ti, is the same probability of proposing Ti when we are at Tj. When this is not the case Hastings corrections are applied. The aim of Metropolis-Hastings algorithm is to produce a collection of states with a determined distribution until the Markov process reaches a stationary distribution. The algorithm has two components:
Although developing, telomerase inhibition within malignant cancer cells can theoretically be used as a potential treatment. Real-time reverse transcription polymerase chain reaction (RT-PCR) quantifying hTERT expression in various tumor samples verified this varying expression. Telomeres in non-cancerous human cells are generally longer than in cancer cells, and telomerase-inhibiting therapy aims to selectively suppress telomerase activity in cancer cells while preserving normal telomerase activity in non-tumor cells. Telomere-targeted treatments include oligonucleotides, nucleosides, small molecule inhibitors, and more. Various natural compounds have been identified as having telomerase inhibitory properties, such as oleic acid, a fatty acid found in vegetable and animal oils.
=== Flow modulation === This is a valve-based approach, where differential flows are used to 'fill' and 'flush' a sample loop. Flow modulation does not suffer from the same volatility restrictions as thermal modulation, as it does not rely on trapping analytes using a cold jet – meaning volatiles <C5 can be efficiently modulated.
=== Discussions with other members of Maduro's government === According to anonymous sources, Reuters reported that United States officials established conversations with Venezuelan minister of interior Diosdado Cabello months before, in order to avoid using the security services or militant ruling-party supporters to target the Venezuelan opposition in case of an attack. According to the Miami Herald, a circle of Venezuelan officials centered on Delcy Rodríguez and her brother, Jorge, privately outlined a roadmap for post-Maduro Venezuela, in which Delcy would act as figurehead and exiled general Miguel Rodríguez Torres (no relationship to the Rodriguez siblings) would lead a "transitional government", dubbed "Madurismo without Maduro"; in return, Venezuela would welcome US investors and gradually loosen ties to US rivals such as Iran and Russia. The Venezuelan proposals were made to US envoy Richard Grenell through Qatari channels; the Trump administration reportedly rejected the overtures. According to the Financial Times, Delcy Rodríguez's brother Jorge Rodríguez had held talks with the United States government in 2025 to have his sister lead a post-Maduro transitional government, though those talks had included Maduro being allowed to go into exile instead of being captured. Anonymous sources speaking for The Guardian said that Delcy and Jorge Rodríguez were communicating with the American and Qatar officials. According to American officials she told them in December that "'Maduro needs to go" and stating "I'll work with whatever is the aftermath.'"
Sources: en.wikipedia.org
=== Mobility === When "Ca. M. multicellularis" is free-swimming, it travels along elongated helical or straight pathways. The consortium has a co-ordinated flagellar rotation, where the organism's body rotates about its axis at the same time and in the same direction as its trajectory. This appears to prevent the formation of a single flagellar bundle while swimming. Under free-swimming conditions, the organism displays spontaneous and temporary shifts back-and-forth along magnetic field lines, known as "ping pong movement" or "escape motility". These rapid directional changes, of nearly 180°, have been interpreted as consistent with a synchronised reversal of flagellar rotation. This movement allows the organism to move more freely under the constraints of a magnetic field.
Omeprazole was first made in 1979 by Swedish AB Hässle, part of Astra AB. It was the first of the proton pump inhibitors (PPI). Astra AB, now AstraZeneca, launched it as an ulcer medicine under the name Losec in Sweden. It was first sold in the United States in 1989 under the brand name Losec. In 1990, at the request of the US Food and Drug Administration, the brand name Losec was changed to Prilosec to avoid confusion with the diuretic Lasix (furosemide). The new name led to confusion between omeprazole (Prilosec) and fluoxetine (Prozac), an antidepressant. Prilosec is owned by Procter & Gamble in alliance with AstraZeneca and the product is designed to address frequent heartburn, which can be triggered by various factors such as certain foods, stress, and smoking. Prilosec was first introduced in 1989 as a prescription medication approved by the FDA for the treatment of severe heartburn. In 2003, Prilosec OTC was launched as the first over-the-counter option for managing frequent heartburn. It is known for its advertising campaign featuring Larry the Cable Guy as the spokesperson for the brand, during the 2010s, emphasizing the concept of "Zero Heartburn".
=== Draining === Once the cheese curd is judged to be ready, the cheese whey must be released. As with many foods the presence of water and the bacteria in it encourages decomposition. To prevent such decomposition it is necessary to remove most of the water (whey) from the cheese milk, and hence cheese curd, to make a partial dehydration of the curd. There are several ways to separate the curd from the whey.
Cross-flowing is a passive formation method that involves the continuous and aqueous phases running at an angle to each other. Most commonly, the channels are perpendicular in a T-shaped junction with the dispersed phase intersecting the continuous phase; other configurations such as a Y-junction are also possible. The dispersed phase extends into the continuous and is stretched until shear forces break off a droplet. In a T-junction, droplet size and formation rate are determined by the flow rate ratio and capillary number. The capillary number relates the viscosity of the continuous phase, the superficial velocity of the continuous phase, and the interfacial tension. Typically, the dispersed phase flow rate is slower than the continuous flow rate. T-junction formation can be further applied by adding additional channels, creating two T-junctions at one location. By adding channels, different dispersed phases can be added at the same point to create alternating droplets of different compositions. Droplet size, usually above 10 μm, is limited by the channel dimensions and often produces droplets with a CV of less than 2% with a rate of up to 7 kHz.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.